title: Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma.
abstract: We have studied the effect of RG 12525, an oral leukotriene D4 (LTD4) antagonist, on LTD4-induced bronchoconstriction in eight male subjects with mild asthma (baseline FEV1 greater than 80% predicted) in a double-blind, placebo-controlled fashion. RG 12525 800 mg displaced the dose-response curve for LTD4 to the right. The mean (95% confidence intervals) difference in log PC20FEV1 following RG 12525 and placebo was 2.88 (1.61, 4.17) doubling doses of LTD4 (P less than 0.01), a 7.5 fold difference. We conclude that RG 12525 when administered orally is an effective LTD4 antagonist in subjects with mild asthma.
authors.affiliation: Respiratory Medicine Unit, City Hospital, Nottingham.
authors.forename: I
authors.initials: I
authors.lastname: Wahedna
authors.forename: A S
authors.initials: AS
authors.lastname: Wisniewski
authors.forename: A E
authors.initials: AE
authors.lastname: Tattersfield
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000503:physiopathology*; D016084:Bronchoconstriction / Q000187:drug effects*; D004311:Double-Blind Method; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000494:pharmacology*; D013189:SRS-A / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D011804:Quinolines; D013189:SRS-A; D013777:Tetrazoles; C059101:RG 12525